Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment Forecast

Diagnostics & Research is Zen Rated B and is the 40th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Price	Price Target	Upside/Downside	Consensus	Analysts	Fore. Revenue Growth	Fore. Earnings Growth	Forecast ROE	Forecast ROA
LH	LABCORP HOLDINGS INC	$30.12B	$370.88	$359.78	-2.99%	Strong Buy	9	5.01%	21.38%	21.04%	9.84%
NEOG	NEOGEN CORP	$2.55B	$11.67	$14.00	19.97%	Strong Buy	2	-0.45%	N/A	-1.14%	-0.72%
CDNA	CAREDX INC	$4.24B	$80.77	$72.67	-10.03%	Strong Buy	3	8.36%	-13.48%	24.69%	18.00%
DGX	QUEST DIAGNOSTICS INC	$28.43B	$258.44	$255.00	-1.33%	Buy	6	3.91%	8.76%	20.55%	9.11%
SHC	SOTERA HEALTH CO	$4.65B	$16.27	$21.00	29.07%	Buy	5	4.44%	25.66%	49.57%	10.73%
CSTL	CASTLE BIOSCIENCES INC	$1.06B	$34.42	$43.25	25.65%	Strong Buy	4	8.21%	N/A	3.45%	2.85%
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$16.57B	$345.80	$333.08	-3.68%	Strong Buy	12	2.58%	139.38%	21.57%	9.34%
DHR	DANAHER CORP	$166.11B	$236.11	$244.54	3.57%	Strong Buy	14	5.93%	19.01%	15.34%	8.82%
A	AGILENT TECHNOLOGIES INC	$50.15B	$177.88	$177.17	-0.40%	Strong Buy	19	4.79%	13.49%	33.44%	17.63%
IQV	IQVIA HOLDINGS INC	$45.34B	$275.15	$310.25	12.76%	Strong Buy	12	4.84%	24.57%	44.74%	9.78%
NEO	NEOGENOMICS INC	$2.19B	$16.96	$23.25	37.09%	Strong Buy	4	7.53%	N/A	10.12%	5.88%
WAT	WATERS CORP	$46.74B	$475.52	$461.37	-2.98%	Strong Buy	19	11.34%	97.87%	13.79%	8.75%
MTD	METTLER TOLEDO INTERNATIONAL INC	$34.84B	$1,751.38	$1.61k	-7.94%	Buy	12	4.06%	8.30%	1,651.49%	34.71%
TMO	THERMO FISHER SCIENTIFIC INC	$266.10B	$718.20	$693.27	-3.47%	Buy	15	4.56%	17.61%	23.08%	11.06%
QGEN	QIAGEN NV	$10.43B	$50.51	$47.38	-6.21%	Hold	8	4.51%	16.97%	18.77%	10.97%
BLLN	BILLIONTOONE INC	$5.35B	$112.00	$128.60	14.82%	Strong Buy	5	15.59%	15.09%	N/A	N/A
ILMN	ILLUMINA INC	$32.49B	$214.91	$262.86	22.31%	Buy	14	6.05%	7.03%	38.82%	17.92%
IDXX	IDEXX LABORATORIES INC	$54.89B	$696.64	$728.00	4.50%	Buy	6	7.17%	9.23%	90.07%	45.42%
MEDP	MEDPACE HOLDINGS INC	$18.59B	$664.54	$653.56	-1.65%	Hold	9	5.50%	6.65%	112.82%	28.66%
RVTY	REVVITY INC	$17.75B	$159.10	$161.50	1.51%	Buy	10	3.74%	46.56%	11.32%	6.79%
STIM	NEURONETICS INC	$156.23M	$2.01	$6.00	198.51%	Strong Buy	2	7.06%	N/A	-127.14%	-18.02%
BNR	BURNING ROCK BIOTECH LTD	$137.60M	$12.67	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FLGT	FULGENT GENETICS INC	$720.27M	$25.78	$25.00	-3.03%	Hold	1	8.56%	N/A	-4.60%	-4.23%
RDNT	RADNET INC	$6.14B	$77.94	$89.33	14.62%	Strong Buy	3	9.56%	N/A	8.53%	2.23%
ICLR	ICON PLC	$15.33B	$204.63	$206.07	0.70%	Buy	14	3.79%	31.51%	12.33%	6.93%
PRPO	PRECIPIO INC	$42.34M	$23.65	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TWST	TWIST BIOSCIENCE CORP	$8.29B	$132.13	$153.00	15.80%	Buy	11	21.76%	N/A	37.88%	25.11%
QUCY	QUANTUM CYBER NV	$58.01M	$0.69	N/A	N/A	N/A	N/A	304.54%	N/A	N/A	N/A
NTRA	NATERA INC	$45.24B	$311.98	$397.03	27.26%	Strong Buy	20	15.45%	N/A	23.88%	16.24%
GRAL	GRAIL INC	$5.61B	$124.74	$128.80	3.25%	Buy	10	19.54%	N/A	-13.62%	-12.24%
MYGN	MYRIAD GENETICS INC	$543.88M	$5.67	$4.91	-13.46%	Hold	7	0.05%	N/A	-11.28%	-4.98%
BDSX	BIODESIX INC	$111.11M	$10.02	$34.20	241.32%	Strong Buy	5	12.51%	N/A	-132.12%	-12.20%
OPK	OPKO HEALTH INC	$1.27B	$1.71	$4.00	133.92%	Strong Buy	2	-12.73%	N/A	N/A	N/A
GH	GUARDANT HEALTH INC	$21.02B	$155.35	$197.65	27.23%	Strong Buy	20	25.97%	N/A	-194.82%	28.51%
ACRS	ACLARIS THERAPEUTICS INC	$658.24M	$4.15	$12.33	197.18%	Strong Buy	3	-3.73%	N/A	-85.54%	-66.01%
XGN	EXAGEN INC	$127.43M	$5.26	$10.17	93.29%	Strong Buy	6	8.92%	N/A	8.01%	1.88%
BIAF	BIOAFFINITY TECHNOLOGIES INC	$4.35M	$2.39	N/A	N/A	N/A	N/A	N/A	N/A	-384.13%	-199.07%
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$80.83M	$2.47	$8.50	244.13%	Strong Buy	2	160.05%	N/A	N/A	-70.29%
FRNM	FREENOME INC	$1.15B	$10.77	$18.00	67.13%	Strong Buy	5	114.28%	N/A	N/A	-34.38%
TRIB	TRINITY BIOTECH PLC	$3.67M	$5.88	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-5.93%
XWEL	XWELL INC	$4.64M	$0.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VNRX	VOLITIONRX LTD	$2.51M	$0.18	$4.00	2,073.91%	Strong Buy	1	120.69%	N/A	-25.97%	100.63%
ISPC	ISPECIMEN INC	$1.86M	$0.74	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
DRIO	DARIOHEALTH CORP	$23.42M	$2.39	$9.00	276.57%	Strong Buy	4	18.99%	N/A	4.90%	2.79%
MBAI	MBODY AI LTD	$2.02M	$2.01	$10.00	397.51%	Buy	1	N/A	-88.81%	5.66%	2.60%
PSNL	PERSONALIS INC	$1.72B	$15.88	$14.63	-7.90%	Hold	4	23.99%	N/A	-30.16%	-21.99%
MDXH	MDXHEALTH SA	$713.97k	$0.14	$2.25	1,518.71%	Strong Buy	3	9.74%	N/A	N/A	N/A
ADVB	ADVANCED BIOMED INC	$3.49M	$2.11	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NDRA	ENDRA LIFE SCIENCES INC	$7.15M	$4.77	$25.00	424.11%	Buy	1	N/A	N/A	-73.71%	-58.56%
SERA	SERA PROGNOSTICS INC	$79.14M	$1.99	$6.00	201.51%	Buy	1	317.08%	N/A	-30.94%	-20.29%

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Nov 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) is the #1 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Labcorp Holdings (NYSE:LH) is: Value: C, Growth: B, Momentum: B, Sentiment: C, Safety: A, Financials: C, and AI: C.

Labcorp Holdings (NYSE:LH) has a Due Diligence Score of 41, which is 12 points higher than the diagnostic & research industry average of 29.

LH passed 15 out of 38 due diligence checks and has strong fundamentals. Labcorp Holdings has seen its stock return 42.03% over the past year, overperforming other diagnostic & research stocks by 17 percentage points.

Labcorp Holdings has an average 1 year price target of $359.78, a downside of -2.99% from Labcorp Holdings's current stock price of $370.88.

Labcorp Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 9 analysts covering Labcorp Holdings, 55.56% have issued a Strong Buy rating, 11.11% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Neogen (NASDAQ:NEOG)

Neogen (NASDAQ:NEOG) is the #2 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Neogen (NASDAQ:NEOG) is: Value: C, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: C, and AI: C.

Neogen (NASDAQ:NEOG) has a Due Diligence Score of 13, which is -16 points lower than the diagnostic & research industry average of 29. Although this number is below the industry average, our proven quant model rates NEOG as a "B".

NEOG passed 4 out of 33 due diligence checks and has weak fundamentals. Neogen has seen its stock return 83.49% over the past year, overperforming other diagnostic & research stocks by 58 percentage points.

Neogen has an average 1 year price target of $14.00, an upside of 19.97% from Neogen's current stock price of $11.67.

Neogen stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Neogen, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Caredx (NASDAQ:CDNA)

Caredx (NASDAQ:CDNA) is the #3 top diagnostic & research stock out of 50 with a Zen Rating of B. Stocks with a rating of B have had an average return of +17.17% per year. Learn more.

The Component Grade breakdown for Caredx (NASDAQ:CDNA) is: Value: C, Growth: B, Momentum: A, Sentiment: A, Safety: C, Financials: C, and AI: D.

Caredx (NASDAQ:CDNA) has a Due Diligence Score of 53, which is 24 points higher than the diagnostic & research industry average of 29.

CDNA passed 18 out of 33 due diligence checks and has strong fundamentals. Caredx has seen its stock return 383.65% over the past year, overperforming other diagnostic & research stocks by 358 percentage points.

Caredx has an average 1 year price target of $72.67, a downside of -10.03% from Caredx's current stock price of $80.77.

Caredx stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Caredx, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 4.53%, which is 3 percentage points higher than the diagnostic & research industry average of 1.18%.

Qiagen Nv's dividend payout ratio of 255.5% indicates that its high dividend yield might not be sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.31%, which is the same as the diagnostic & research industry average of 1.18%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 33.2% indicates that its dividend yield is sustainable for the long-term.

3. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 0.78%, which is the same as the diagnostic & research industry average of 1.18%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 23.5% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.09% in the last day, and up 0.07% over the last week. Exagen was the among the top losers in the diagnostics & research industry, dropping -25.92% yesterday.

Exagen shares are trading lower after the company reported mixed Q3 financial results.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Sotera Health Co has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Sotera Health Co's stock has gained 3.37% in the past year. It has underperformed other stocks in the diagnostic & research industry by -22 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 30 points higher than the diagnostic & research industry average of 13. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 17% in the past year. It has underperformed other stocks in the diagnostic & research industry by -8 percentage points.

3. Danaher (NYSE:DHR)

Danaher (NYSE:DHR) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Danaher has a valuation score of 29, which is 16 points higher than the diagnostic & research industry average of 13. It passed 2 out of 7 valuation due diligence checks.

Danaher's stock has gained 11.81% in the past year. It has underperformed other stocks in the diagnostic & research industry by -14 percentage points.

Are diagnostic & research stocks a good buy now?

57.14% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 2.57% over the next year.

0% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 28.21% of diagnostic & research stocks are rated B (Buy), 64.1% are rated C (Hold), 7.69% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 30.27x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.